On April 16, 2025, Channel Therapeutics Corp entered into a merger agreement with LNHC, where LNHC will become a wholly-owned subsidiary of Channel, and Channel will issue approximately 50,100 shares of Series A Preferred Stock for $50.1 million as part of a PIPE financing, with stockholder approval obtained for the transaction.